Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of approximately CAD3,909,600.

Helix-BioPharma-Closes-Private-Placement-19Oct2017.pdf